Latest Cell Therapeutics Inc. Stories
SEATTLE, April 19, 2012 /PRNewswire/ -- On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss the Company's 2012 first quarter achievements and financial results. Conference Call Numbers Friday, April 208:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-800-762-8779 (US Participants)1-480-629-9645...
SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus Associated Kinase 2) selective inhibitor that has demonstrated encouraging clinical benefit in phase 1 and 2 clinical studies in...
SEATTLE, April 18, 2012 /PRNewswire/ -- On Thursday, April 19, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call. Conference Call Numbers Thursday, April 198:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-8609 (US Participants)1-480-629-9692 (International) Call-back numbers for post-listening available at 11:30 a.m....
NEW YORK, April 6, 2012 /PRNewswire/ -- The following statement is being issued by Brower Piven regarding the proposed settlement of the Cell Therapeutics, Inc. class action. UNITED STATES DISTRICT COURTWESTERN DISTRICT OF WASHINGTONAT SEATTLE In re CELL THERAPEUTICS, INC.CLASS ACTION LITIGATIONThis Document Relates To: All Actions Master Docket No. C10-414 MJP(consolidated with Nos. C10-480 MJP and C10-559MJP)CLASS ACTION SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION...
NEW YORK, March 30, 2012 /PRNewswire/ -- The following statement is being issued by Brower Piven regarding the proposed settlement of the Cell Therapeutics, Inc. class action. UNITED STATES DISTRICT COURTWESTERN DISTRICT OF WASHINGTONAT SEATTLE In re CELL THERAPEUTICS, INC.CLASS ACTION LITIGATIONThis Document Relates To: All Actions Master Docket No. C10-414 MJP(consolidated with Nos. C10-480 MJP and C10-559MJP)CLASS ACTION SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION...
SEATTLE, March 27, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that the University of Washington's ("UW") School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO(TM) (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy ("RT") to the combination of temozolomide ("TMZ") and RT for patients with...
SEATTLE, March 7, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011. Fourth Quarter and Year End Results For the quarter ended December 31, 2011, total net operating expenses were $9.9 million compared to $16.3 million for the same period in 2010. Net loss attributable to common shareholders was $17.9 million ($0.09 per share) for...
SEATTLE, March 6, 2012 /PRNewswire/ -- On Wednesday, March 7, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss the Company's 2011 fourth quarter and year-end achievements and financial results. Conference Call NumbersWednesday, March 78:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-8609 (US...
VANCOUVER, British Columbia, Feb. 21, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: JDS Uniphase (NASDAQ:JDSU), Arch Coal (NYSE:ACI), Cell Therapeutics (NASDAQ:CTIC), SunPower (NASDAQ:SPWR), and Zynga (NASDAQ:ZNGA). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...
SEATTLE, Feb. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that Pixuvri(TM) (pixantrone dimaleate) has been granted a positive opinion for conditional approval from the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"). Based on the CHMP's recommendation, CTI expects that a conditional marketing authorization for Pixuvri should be granted by the European Commission within the next few...
